TrialLancet (London, England)2023

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.

Siow Ming Lee et al.PubMed ↗Publisher ↗

No numbers read from the abstract.